Aarti Drugs
Ticker > Company >

Aarti Drugs share price

Aarti Drugs Ltd.

NSE: AARTIDRUGS BSE: 524348 SECTOR: Pharmaceuticals & Drugs  1.86 L   954   231

514.90
+4.25 (0.83%)
BSE: 17 Sep 04:01 PM

Price Summary

Today's High

₹ 518.15

Today's Low

₹ 505.55

52 Week High

₹ 574.95

52 Week Low

₹ 312.5

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 4699.49 Cr.

Enterprise Value

₹ 5208.83 Cr.

No. of Shares

9.13 Cr.

P/E

26.25

P/B

3.62

Face Value

₹ 10

Div. Yield

0.19 %

Book Value (TTM)

₹  142.43

CASH

₹ 4.57 Cr.

DEBT

₹ 513.91 Cr.

Promoter Holding

55.22 %

EPS (TTM)

₹  19.62

Sales Growth

-4.11%

ROE

12.97 %

ROCE

13.53%

Profit Growth

10.88 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-4.11%
3 Year-1.16%
5 Year5.86%

Profit Growth

1 Year10.88%
3 Year-6.91%
5 Year3%

ROE%

1 Year12.97%
3 Year13.34%
5 Year19.22%

ROCE %

1 Year13.53%
3 Year14.2%
5 Year19.35%

Debt/Equity

0.4107

Price to Cash Flow

21.35

Interest Cover Ratio

7.1717

CFO/PAT (5 Yr. Avg.)

1.0090993989184

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 55.22 0.00
Mar 2025 55.48 0.00
Dec 2024 55.38 0.00
Sep 2024 55.64 0.00
Jun 2024 55.67 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 82.5053 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.0090993989184.
  • The company has a high promoter holding of 55.22%.

 Limitations

  • The company has shown a poor profit growth of -6.90784469753671% for the Past 3 years.
  • The company has shown a poor revenue growth of -1.16125821558689% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 492.96 543.09 514.54 622.96 520.96
Total Expenditure 438.74 483.55 454.29 534.3 457.01
Operating Profit 54.22 59.54 60.25 88.66 63.95
Other Income 0.11 0.38 11.37 1.71 0.38
Interest 7.46 7.17 7.57 7.48 6.82
Depreciation 11.71 11.86 12.02 12.21 12.27
Exceptional Items 0 0 0 0 0
Profit Before Tax 35.16 40.89 52.03 70.68 45.24
Tax 8.25 10.5 13.5 9.2 -3.4
Profit After Tax 26.91 30.39 38.53 61.48 48.64
Adjusted EPS (Rs) 2.93 3.33 4.22 6.74 5.33

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 1914.89 2251.17 2497.97 2266.91 2173.65
Total Expenditure 1510.52 1930.01 2211.92 1997.74 1908.48
Operating Profit 404.37 321.17 286.05 269.18 265.18
Other Income 6.42 4.77 2.23 4.18 13.57
Interest 25.71 23.05 36.18 33.21 32.2
Depreciation 47.6 47.39 47.29 47.67 47.79
Exceptional Items 0.22 0 0 0 0
Profit Before Tax 337.71 255.5 204.81 192.48 198.75
Tax 80 60.5 52 50.6 41.44
Net Profit 257.71 195 152.81 141.88 157.31
Adjusted EPS (Rs.) 27.65 21.06 16.5 15.43 17.24

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 93.2 92.6 92.6 91.94 91.27
Total Reserves 766.41 879.57 1021.7 1083.27 1160.08
Borrowings 147.56 118.33 161.89 238.26 237.95
Other N/C liabilities 107.94 89.34 71.91 73.56 77.71
Current liabilities 521.89 854.68 847.39 684.6 705.79
Total Liabilities 1637.01 2034.52 2195.5 2171.62 2272.79
Assets
Net Block 630.52 649.41 634.48 722.29 761.23
Capital WIP 15.95 59.62 160.75 221.62 273.4
Intangible WIP 0 0 0 0 0
Investments 24.32 28.03 28.62 29.97 42.4
Loans & Advances 6.09 24.26 22.11 16.71 15.2
Other N/C Assets 0 0 0 0 0
Current Assets 960.13 1273.19 1349.53 1181.02 1180.56
Total Assets 1637.01 2034.52 2195.5 2171.62 2272.79
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 337.71 255.5 204.81 192.48 198.75
Adjustment 65.35 66.76 78.43 77.69 70.08
Changes in Assets & Liabilities -161.11 -202.27 -66.71 118.17 3.19
Tax Paid -87.78 -80.09 -54.83 -51.23 -51.95
Operating Cash Flow 154.18 39.9 161.7 337.1 220.08
Investing Cash Flow -69.03 -125.36 -131.14 -187.09 -134.92
Financing Cash Flow -85.28 84.11 -30.54 -148.81 -84.6
Net Cash Flow -0.13 -1.35 0.03 1.2 0.56

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 55.67 55.64 55.38 55.48 55.22
aarnav rashesh gogri 0.20 0.20 0.20 0.20 0.20
aarti life science llp 0.01 0.01 0.01 0.01 0.01
aashay rashesh gogri 0.96 0.96 0.96 0.96 0.96
aashyav business trust (a... 1.50 1.50 1.50 1.50 1.50
adhish p. patil 1.24 1.24 1.24 1.25 1.25
alchemie financial servic... 0.04 0.04 0.04 0.04 0.04
alchemie finserv pvt. ltd... 2.21 2.21 2.21 2.21 2.21
anushakti enterprise priv... 2.62 2.62 2.62 2.62 2.62
arati tushar sankhe 0.19 0.19 0.19 0.19 0.19
arti rajendra gogri 0.15 0.15 0.15 0.15 0.15
arun moreshwar patil 0.08 0.08 0.08 0.08 0.08
bhoomi harshit savla 1.09 1.09 1.09 1.09 1.09
chandrakant vallabhaji go... 1.87 1.87 1.87 1.87 1.87
dilesh roadlines pvt ltd 0.54 0.54 0.54 0.54 0.54
gogri finserv pvt. ltd. 3.80 3.80 3.80 3.80 3.80
harshit m. savla (huf) (k... 0.01 0.01 0.01 0.01 0.01
harshit manilal savla 4.74 4.74 4.74 4.74 4.74
hetal gogri gala 3.06 3.05 3.05 3.05 3.05
hriman savla 0.02 0.02 0.01 0.01 0.01
indira madan dedhia 0.21 0.21 0.21 0.21 0.21
jay manilal savla 0.28 0.28 0.27 0.27 0.27
jaya chandrakant gogri 1.71 1.71 1.71 1.71 1.71
jigna hiren shah 0.50 0.50 0.50 0.50 0.50
kalika amit mishra 0.03 0.03 0.03 0.03 0.03
kenisha savla 0.02 0.02 0.01 0.01 0.01
manisha rashesh gogri 0.20 0.20 0.20 0.20 0.20
mirik rajendra gogri 0.80 0.80 0.70 0.70 0.70
orchid family trust (rela... 0.99 0.99 0.99 0.99 0.87
paridhi business trust (s... 0.64 0.64 0.64 0.64 0.64
prakash m. patil (huf) (k... 0.18 0.18 0.18 0.18 0.18
prakash moreshwar patil 9.24 9.23 9.23 9.32 9.32
priti prakash patil 4.40 4.40 4.40 4.40 4.40
rajendra vallabhaji gogri... 0.11 0.11 0.11 0.11 0.11
rashesh chandrakant gogri... 4.65 4.64 4.64 4.64 4.64
renil rajendra gogri 0.80 0.80 0.66 0.66 0.66
safechem enterprises priv... 0.61 0.61 0.61 0.61 0.61
seema harshit savla 3.84 3.84 3.84 3.84 3.84
tulip family trust (gloir... 1.01 1.01 1.01 1.01 0.88
uday moreshwar patil 0.06 0.06 0.06 0.06 0.06
vikas moreshwar patil 0.04 0.04 0.04 0.04 0.04
vishwa harshit savla 1.03 1.03 1.03 1.03 1.03
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 44.33 44.36 44.62 44.52 44.78
dsp small cap fund 5.64 5.93 6.45 7.13 7.98
harit pragji shah 2.67 2.67 2.67 2.67 2.67
icici prudential pharma h... - - 1.23 1.52 1.74
investor education and pr... 0.66 - - - 0.68
jayshree harit shah 1.79 1.79 1.78 1.78 1.78
llp 0.08 0.10 0.16 0.16 0.18
investor education and pr... - 0.67 0.68 0.68 -
blend fund 2 1.22 1.14 - - -
nikhil parimal desai 1.06 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ICRA
Credit CRISIL
Credit CRISIL
Credit
Credit
Credit
Credit
Credit
Credit ICRA
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research BP Wealth
Research Nuvama

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY25
Concall Q4FY24
Concall Q4FY21
Concall Q3FY25
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY24
Concall Q2FY22
Concall Q2FY21
Concall Q1FY25
Concall Q1FY24
Concall Q1FY22
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY23
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY25
Presentation Q1FY24
Presentation Q1FY24
Presentation Q1FY23
Presentation Q1FY22
Presentation Q1FY21
Presentation Q1FY19

Company News

Aarti Drugs commences commercial production at Gujarat manufacturing plant 5 Sep, 12:21 PM Aarti Drugs informs about press release 21 Aug, 5:19 PM Aarti Drugs - Quaterly Results 18 Jul, 4:40 PM Aarti Drugs - Quaterly Results 18 Jul, 4:40 PM Aarti Drugs - Quaterly Results 18 Jul, 4:40 PM Aarti Drugs informs about disclosure 7 May, 10:17 AM Aarti Drugs - Quaterly Results 6 May, 4:23 PM Aarti Drugs - Quaterly Results 6 May, 4:23 PM Aarti Drugs - Quaterly Results 6 May, 4:23 PM Aarti Drugs informs about acquisition 4 Feb, 4:43 PM Aarti Drugs gets nod to invest Rs 25 crore in Pinnacle Life Science 30 Jan, 9:38 AM Aarti Drugs - Quaterly Results 29 Jan, 4:41 PM Aarti Drugs - Quaterly Results 29 Jan, 4:41 PM Aarti Drugs - Quaterly Results 29 Jan, 4:41 PM Aarti Drugs inks pact to acquire 26.25% stake in Pro-Zeal Green Power Six 10 Jan, 9:58 AM Aarti Drugs gets EIR from USFDA for Maharashtra API manufacturing facility 24 Dec, 3:44 PM Aarti Drugs’ arm incorporates overseas wholly owned subsidiary 28 Nov, 9:16 AM Aarti Drugs - Quaterly Results 24 Oct, 6:04 PM Aarti Drugs - Quaterly Results 24 Oct, 6:04 PM Aarti Drugs gets GMP certificate from UK MHRA 4 Oct, 11:00 AM USFDA completes inspection at Aarti Drugs’ API manufacturing facility 21 Sep, 10:08 AM USFDA issues EIR to Baddi facility of Aarti Drugs’ arm 30 Jul, 11:41 AM Aarti Drugs - Quaterly Results 26 Jul, 5:29 PM Aarti Drugs - Quaterly Results 26 Jul, 5:29 PM Aarti Drugs - Quaterly Results 26 Jul, 5:29 PM Aarti Drugs informs about conference call 19 Jul, 3:38 PM Aarti Drugs informs about compliances-certificate 10 Jul, 5:18 PM Aarti Drugs - Quaterly Results 3 May, 4:30 PM Aarti Drugs - Quaterly Results 3 May, 4:30 PM Aarti Drugs - Quaterly Results 3 May, 4:30 PM USFDA completes inspection at Baddi facility of Aarti Drugs’ arm 23 Apr, 12:47 PM Aarti Drugs - Quaterly Results 24 Jan, 4:02 PM Aarti Drugs - Quaterly Results 24 Jan, 4:02 PM Aarti Drugs - Quaterly Results 24 Jan, 4:02 PM Aarti Drugs - Quaterly Results 19 Oct, 4:00 PM Aarti Drugs - Quaterly Results 19 Oct, 4:00 PM Aarti Drugs - Quaterly Results 19 Oct, 4:00 PM Aarti Drugs informs about newspaper clipping 28 Aug, 3:20 PM Aarti Drugs - Quaterly Results 21 Jul, 4:42 PM Aarti Drugs - Quaterly Results 21 Jul, 4:42 PM Aarti Drugs - Quaterly Results 21 Jul, 4:42 PM Aarti Drugs wins Pharmexcil Outstanding Exports Awards 2021-22 7 Jul, 12:22 PM Aarti Drugs informs about disclosure 2 May, 2:58 PM Aarti Drugs - Quaterly Results 29 Apr, 6:50 PM Aarti Drugs - Quaterly Results 29 Apr, 6:50 PM Aarti Drugs informs about analyst meet 28 Feb, 4:43 PM Aarti Drugs informs about loss of share certificate 25 Feb, 10:53 AM Aarti Drugs - Quaterly Results 27 Jan, 4:43 PM Aarti Drugs - Quaterly Results 27 Jan, 4:43 PM Aarti Drugs - Quaterly Results 27 Jan, 4:43 PM

Aarti Drugs Stock Price Analysis and Quick Research Report. Is Aarti Drugs an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Aarti Drugs. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Aarti Drugs has a PE ratio of 26.2687023679046 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Aarti Drugs has ROA of 7.0792% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Aarti Drugs has a Current ratio of 1.6727.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Aarti Drugs has a ROE of 12.9661%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Aarti Drugs has a Debt to Equity ratio of 0.4107 which means that the company has low proportion of debt in its capital.

  • Sales growth: Aarti Drugs has reported revenue growth of -4.1138% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Aarti Drugs for the current financial year is 12.1995584487676%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Aarti Drugs is Rs 1 and the yield is 0.1943%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Aarti Drugs is Rs 19.6165. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Aarti Drugs in Ticker for free. Also, one can get the intrinsic value of Aarti Drugs by using Valuation Calculators, which are available with a Finology ONE subscription. 

Aarti Drugs FAQs

Q1. What is Aarti Drugs share price today?
Ans: The current share price of Aarti Drugs is Rs 515.3.

Q2. What is the market capitalisation of Aarti Drugs?
Ans: Aarti Drugs has a market capitalisation of Rs 4703.1431 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Aarti Drugs?
Ans: The PE ratio of Aarti Drugs is 26.2687023679046 and the P/B ratio of Aarti Drugs is 3.61782613091293, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Aarti Drugs share?
Ans: The 52-week high share price of Aarti Drugs is Rs 564.05, and the 52-week low share price of Aarti Drugs is Rs 312.

Q5. Does Aarti Drugs pay dividends?
Ans: Currently, Aarti Drugs pays dividends. Dividend yield of Aarti Drugs is around 0.1943%.

Q6. What are the face value and book value of Aarti Drugs shares?
Ans: The face value of Aarti Drugs shares is Rs 10, while the book value per share of Aarti Drugs is around Rs 142.4336. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Aarti Drugs?
Ans: Aarti Drugs has a total debt of Rs 513.9125 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Aarti Drugs?
Ans: The ROE of Aarti Drugs is 12.9661% and ROCE of Aarti Drugs is 13.5327%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Aarti Drugs a good buy for the long term?
Ans: The Aarti Drugs long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Aarti Drugs undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Aarti Drugs appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Aarti Drugs’s financials?
Ans: You can review Aarti Drugs’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Aarti Drugs

Aarti Drugs Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Aarti Drugs Ltd. is a pharmaceutical company that specializes in the manufacturing and distribution of active pharmaceutical ingredients (APIs), intermediates, specialty chemicals, and pharmaceutical formulations. The company was established in XXXX and has since grown to become a prominent player in the industry.

Aarti Drugs Ltd. - Share Price

The share price of Aarti Drugs Ltd. reflects the market valuation of the company's stock. As a long-term stock investor, it is essential to analyze the company's share price trends, historical performance, and market sentiment before making any investment decisions. Our pre-built screening tools can help you analyze the stock's performance and identify potential buying or selling opportunities.

Aarti Drugs Ltd. - Balance Sheet Analysis

Analyzing the balance sheet of Aarti Drugs Ltd. can provide valuable insights into the financial health of the company. By examining the company's assets, liabilities, and shareholders' equity, investors can assess its solvency, liquidity, and overall financial stability. Our premium features, including tools such as DCF Analysis, BVPS Analysis, and DuPont analysis, can assist in calculating the fair value and evaluating the company's financial performance.

Aarti Drugs Ltd. - Annual Report

Aarti Drugs Ltd. publishes an annual report that provides a comprehensive overview of the company's operations, financial performance, and future prospects. The annual report offers insights into the company's business strategy, risk assessment, and growth initiatives. These reports are available for download on our website, allowing investors to delve deeper into the company's financials and make informed investment decisions.

Aarti Drugs Ltd. - Dividend Analysis

Analyzing the dividend history of Aarti Drugs Ltd. can be beneficial for long-term stock investors seeking income-generating opportunities. By examining the company's dividend payout ratio, dividend yield, and dividend growth rate, investors can assess the company's commitment to returning value to its shareholders. Our pre-built screening tools can assist in comparing dividend performance across multiple companies and industries.

Aarti Drugs Ltd. - Quarterly Results

Reviewing the quarterly results of Aarti Drugs Ltd. enables investors to monitor the company's performance on a more frequent basis. By analyzing key financial metrics such as revenue, net profit, and earnings per share, investors can evaluate the company's growth trajectory and profitability. Our premium features, including tools such as DCF Analysis, BVPS Analysis, and DuPont analysis, can aid in measuring the company's financial performance and determining its fair value.

Aarti Drugs Ltd. - Stock Price Analysis

Analyzing the stock price of Aarti Drugs Ltd. can provide insights into market trends, investor sentiment, and the company's growth prospects. By examining historical price data and using technical analysis tools, investors can identify potential buying or selling opportunities. Our pre-built screening tools can help investors track the stock's performance, set price alerts, and create customized watchlists.

Aarti Drugs Ltd. - Price Chart

The price chart of Aarti Drugs Ltd. showcases the historical movement of the stock's price over a specific period. By studying price patterns and trendlines, investors can gain insights into market sentiment and identify potential entry or exit points. Our pre-built screening tools provide interactive and customizable charts that can aid in technical analysis and decision-making.

Aarti Drugs Ltd. - News and Updates

Staying informed about the latest news and updates related to Aarti Drugs Ltd. is crucial for long-term stock investors. Our website provides a dedicated section for company-specific news, regulatory announcements, and market updates. By accessing reliable and timely information, investors can stay ahead of market developments and make informed investment decisions.

Aarti Drugs Ltd. - Conference Call Transcripts

Conference call transcripts offer insights into the discussions between company management and analysts during earnings calls and other important events. These transcripts provide details about the company's performance, growth strategy, and future outlook. Our website provides downloadable conference call transcripts, allowing investors to gain a deeper understanding of Aarti Drugs Ltd.'s operations and prospects.

Aarti Drugs Ltd. - Investor Presentations

Investor presentations provide a comprehensive overview of a company's business model, competitive advantages, and growth strategy. Aarti Drugs Ltd. regularly publishes investor presentations that highlight its key achievements, financial performance, and future plans. These presentations are available for download on our website, enabling investors to assess the company's investment potential and make informed decisions.

Aarti Drugs Ltd. - Promoters

The promoters of Aarti Drugs Ltd. are individuals or entities that have a significant ownership stake in the company. Promoters play a crucial role in the company's decision-making processes and long-term vision. Understanding the background and track record of the promoters can provide insights into their commitment to the company's growth and shareholder value creation.

Aarti Drugs Ltd. - Shareholders

Shareholders of Aarti Drugs Ltd. are individuals or entities that hold shares of the company's stock. Analyzing the shareholding pattern can provide insights into the company's ownership structure, institutional investor interest, and shareholder activism. Our pre-built screening tools can help investors track changes in shareholding patterns and identify significant shareholders in Aarti Drugs Ltd.

Remember, as a long-term stock investor, it is essential to conduct thorough research, evaluate the risks involved, and seek professional advice if required. Our website provides a range of tools and resources to assist you in making informed investment decisions. 

Aarti Drugs Balance Sheet Assessment

Aarti Drugs Equity Increase

Observing Aarti Drugs' balance sheet, we notice that share capital experienced a notable rise from Rs 23.30 Cr in March 2020 to Rs 91.94 Cr by March 2024. This indicates an expansion in the company's equity base possibly attributed to the issuance of additional shares or other equity instruments.

Aarti Drugs Reserves Trajectory

Aarti Drugs has consistently built its total reserves, from Rs 598.49 Cr in March 2020 to Rs 1,083.27 Cr by March 2024. This steady increase in reserves may represent a solid accumulation of earnings, signifying the company's potential sustainability and profitability over this multi-year period.

Aarti Drugs Debt Position

The company's borrowings have fluctuated, increasing from Rs 176.28 Cr in March 2020 to Rs 238.26 Cr by March 2024. Aarti Drugs has demonstrated the capability to leverage for growth while maintaining a manageable debt load relative to the size of the company.

Aarti Drugs Asset Expansion

Total assets of Aarti Drugs have gone up significantly from Rs 1,470.70 Cr in March 2020 to Rs 2,171.62 Cr by March 2024. The growth is particularly evident in net block and capital work in progress (WIP), with the latter increasing from Rs 10.96 Cr to Rs 221.62 Cr, suggesting a focus on long-term asset development and investment.

This analysis is based on the Standalone Balance Sheet of Aarti Drugs and is intended for informational purposes on their stock analysis page.

As market participants scrutinize the pharmaceutical sector on exchanges like NSE/BSE, Aarti Drugs’ financial data is an important element in comprehensive stock screening strategies.

Read More
X